# moderate to severe MDD FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/moderate-to-severe-mdd

> No upcoming FDA catalysts in moderate to severe MDD; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for moderate to severe MDD?

No upcoming FDA catalysts in moderate to severe MDD; 2 past events are recorded. Press release filed with the SEC (EX-99): "On October 31, 2023, the Company announced Phase 2a interim results for CYB003, its proprietary deuterated psilocin molecule, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo, in participants with moderate to severe MDD." [Calendar and source filings](https://sec-api.dev/indications/moderate-to-severe-mdd)

Source: Press release filed with the SEC (EX-99), accession 0001833141-25-000043, https://www.sec.gov/Archives/edgar/data/1833141/000183314125000043/cybin-mdaxq2x26.htm (retrieved 2026-11-12). Last confirmed 2025-11-13. Cite: https://sec-api.dev/indications/moderate-to-severe-mdd#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 31, 2023 | [HLP003 interim data readout](https://sec-api.dev/pdufa/hlp003) | HELP | moderate to severe MDD | completed, met | "On October 31, 2023, the Company announced Phase 2a interim results for HLP003, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12 mg dose compared to placebo, in participants with moderate to severe MDD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314126000058/cybin-mdaxq1x27.htm)) |
| October 31, 2023 | [CYB003 interim data readout](https://sec-api.dev/pdufa/cyb003) | HELP | moderate to severe MDD | completed, met | "On October 31, 2023, the Company announced Phase 2a interim results for CYB003, its proprietary deuterated psilocin molecule, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo, in participants with moderate to severe MDD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314125000043/cybin-mdaxq2x26.htm)) |

## Drugs

- [HLP003](https://sec-api.dev/pdufa/hlp003) (HELP)
- [CYB003](https://sec-api.dev/pdufa/cyb003) (HELP)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/moderate-to-severe-mdd.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "moderate to severe MDD FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/moderate-to-severe-mdd

```bibtex
@misc{secapidev_indications_moderate_to_severe_mdd_20261116,
  title        = {moderate to severe MDD FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/moderate-to-severe-mdd}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_moderate_to_severe_mdd_20261116","title":"moderate to severe MDD FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/moderate-to-severe-mdd","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
